Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer
Clinical Breast Cancer · 2026-07 · 26 (7) · 10-16
DOI: 10.1016/j.clbc.2026.05.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2026-07. Verfasst von Vincenzo Di Lauro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Napoli, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
The clinical benefit of available treatments in metastatic hormone receptor (HR)+/HER2-breast cancer (BC) remains limited due to the onset of resistance mechanisms, hence the need for increasingly personalized therapies targeting specific molecular alterations. In these cancers, the estrogen receptor, CDK4/6, and the phosphoinositide 3-kinase pathway are key drivers of tumor growth and survival. In preclinical studies, targeting these pathways together has been shown to enhance treatment response and delay resistance; in clinical practice, however, implementation of this combination has been limited by its challenging safety profile that results in poor tolerability. PIK3CA mutations are found in around 40% of cases and are associated with a poor prognosis. In BCs with alterations in the AKT/PIK3CA pathway, capivasertib, alpelisib, and inavolisib have recently improved progression-free survival (PFS). Inavolisib (GC0077) differs from the other drugs targeting this pathway by its high potency and tolerability when combined with endocrine therapy, mostly with fulvestrant, and a CDK4/6 inhibitor. Its recent use in the first-line combined treatment for advanced HR+/HER2-negative BC has shown a PFS benefit compared to placebo in the INAVO120 trial, suggesting its role as a valid treatment option in PIK3CA-mutated patients. Further studies are warranted to confirm these results in terms of prolonging efficacy and maintaining durable responses - with a manageable safety profile - in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Napoli, Italy.
- S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. Electronic address: Rizzo.alessandro179@gmail.com.
- Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.
- Division of Medical Oncology, S.G. Moscati Hospital, Università degli Studi della Campania "Luigi Vanvitelli", Avellino, Italy.
- S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
- Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Napoli, Italy; Scuola Superiore Meridionale (SSM), Clinical and Translational Oncology, Naples, Italy.
Zitieren
APA
Di Lauro, V., Rizzo, A., Sacco, P. C., Palma, V., Ciccimarra, F., Cesare, G., De Laurentiis, M., & Massafra, R. (2026). Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer. Clinical Breast Cancer, 26(7), 10-16. https://doi.org/10.1016/j.clbc.2026.05.004
Vancouver
Di Lauro V, Rizzo A, Sacco PC, Palma V, Ciccimarra F, Cesare G, et al. Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer. Clinical Breast Cancer. 2026;26(7):10-16. doi:10.1016/j.clbc.2026.05.004
BibTeX
@article{DiLauro2026,
author = {Di Lauro, Vincenzo and Rizzo, Alessandro and Sacco, Paola C and Palma, Valentina and Ciccimarra, Francesco and Cesare, Gridelli and De Laurentiis, Michelino and Massafra, Raffaella},
title = {Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {7},
pages = {10--16},
doi = {10.1016/j.clbc.2026.05.004}
}
EUVIMED